{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:53:27Z","timestamp":1793642007450,"version":"4.5.1"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.intimp.2023.110072","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T06:32:09Z","timestamp":1680503529000},"page":"110072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling"],"prefix":"10.1016","volume":"118","author":[{"given":"Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-4379","authenticated-orcid":false,"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.intimp.2023.110072_b0005","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.jacc.2019.10.009","article-title":"The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond","volume":"74","author":"Mensah","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.intimp.2023.110072_b0010","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.jchf.2019.06.004","article-title":"Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction","volume":"7","author":"Aimo","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"17","key":"10.1016\/j.intimp.2023.110072_b0015","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2011.07.022","article-title":"Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry","volume":"58","author":"Gaasch","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"10.1016\/j.intimp.2023.110072_b0020","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovic","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.intimp.2023.110072_b0025","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.7150\/thno.53326","article-title":"The pivotal roles of exosomes derived from endogenous immune cells and exogenous stem cells in myocardial repair after acute myocardial infarction","volume":"11","author":"Xiong","year":"2021","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.intimp.2023.110072_b0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","article-title":"Metabolic remodelling in heart failure","volume":"15","author":"Bertero","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.intimp.2023.110072_b0035","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/cvr\/cvz336","article-title":"Cardiac monocytes and macrophages after myocardial infarction","volume":"116","author":"Peet","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.intimp.2023.110072_b0040","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.mam.2018.07.001","article-title":"Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities","volume":"65","author":"Frangogiannis","year":"2019","journal-title":"Mol Aspects Med"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/CIRCRESAHA.119.311148","article-title":"The Extracellular Matrix in Ischemic and Nonischemic Heart Failure","volume":"125","author":"Frangogiannis","year":"2019","journal-title":"Circ Res"},{"issue":"11","key":"10.1016\/j.intimp.2023.110072_b0050","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCRESAHA.119.313682","article-title":"Leveraging Signaling Pathways to Treat Heart Failure With Reduced Ejection Fraction","volume":"124","author":"Pinilla-Vera","year":"2019","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.intimp.2023.110072_b0055","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/CIRCRESAHA.118.311403","article-title":"G-Protein-Coupled Receptors in Heart Disease","volume":"123","author":"Wang","year":"2018","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCULATIONAHA.118.036065","article-title":"Dysfunctional and Proinflammatory Regulatory T-Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy","volume":"139","author":"Bansal","year":"2019","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.intimp.2023.110072_b0065","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.jacc.2018.02.066","article-title":"Trehalose-Induced Activation of Autophagy Improves Cardiac Remodeling After Myocardial Infarction","volume":"71","author":"Sciarretta","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0070","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pcad.2019.11.009","article-title":"Left ventricular hypertrophy and hypertension","volume":"63","author":"Yildiz","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0075","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.113.001878","article-title":"Pathological ventricular remodeling: mechanisms: part 1 of 2","volume":"128","author":"Burchfield","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2023.110072_b0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.yjmcc.2016.08.018","article-title":"Regulation of cardiac hypertrophy and remodeling through the dual-specificity MAPK phosphatases (DUSPs)","volume":"101","author":"Liu","year":"2016","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0085","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCRESAHA.115.308238","article-title":"DUSP8 Regulates Cardiac Ventricular Remodeling by Altering ERK1\/2 Signaling","volume":"119","author":"Liu","year":"2016","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.intimp.2023.110072_b0090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.intimp.2023.110072_b0095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The Transition From Hypertension to Heart Failure: Contemporary Update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.intimp.2023.110072_b0105","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10.1016\/j.intimp.2023.110072_b0110","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.intimp.2023.110072_b0115","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"10254","key":"10.1016\/j.intimp.2023.110072_b0120","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.intimp.2023.110072_b0125","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes","volume":"323","author":"Petrie","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2023.110072_b0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1146\/annurev-pharmtox-052120-014725","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure","volume":"62","author":"Shah","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102417","article-title":"Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial","volume":"16","author":"Requena-Ibanez","year":"2022","journal-title":"Diabetes Metab Syndr"},{"issue":"6","key":"10.1016\/j.intimp.2023.110072_b0145","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.2337\/dc19-2187","article-title":"Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial","volume":"43","author":"Singh","year":"2020","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.intimp.2023.110072_b0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.intimp.2023.110072_b0155","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.intimp.2023.110072_b0160","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"5","key":"10.1016\/j.intimp.2023.110072_b0165","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.intimp.2023.110072_b0170","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.intimp.2023.110072_b0175","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.intimp.2023.110072_b0180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0185","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","article-title":"Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide","volume":"42","author":"Georgianos","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.intimp.2023.110072_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030629","article-title":"Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System","volume":"20","author":"Ansary","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0195","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0200","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.intimp.2023.110072_b0205","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2023.110072_b0210","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13098-017-0275-4","article-title":"Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus","volume":"9","author":"Yagi","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.intimp.2023.110072_b0215","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.mri.2021.11.004","article-title":"Not only how much, but also how to, when measuring epicardial adipose tissue","volume":"86","author":"Requena-Ibanez","year":"2022","journal-title":"Magn Reson Imaging"},{"issue":"8","key":"10.1016\/j.intimp.2023.110072_b0220","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study","volume":"9","author":"Requena-Ibanez","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.intimp.2023.110072_b0225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.intimp.2023.110072_b0230","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11357-022-00563-x","article-title":"SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice","volume":"44","author":"Soares","year":"2022","journal-title":"Geroscience"},{"issue":"8","key":"10.1016\/j.intimp.2023.110072_b0235","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","article-title":"SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients","volume":"79","author":"Mone","year":"2022","journal-title":"Hypertension"},{"issue":"16","key":"10.1016\/j.intimp.2023.110072_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168786","article-title":"Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.intimp.2023.110072_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107832","article-title":"Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors","volume":"224","author":"Ugusman","year":"2021","journal-title":"Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.intimp.2023.110072_b0250","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","article-title":"Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty","volume":"15","author":"Ferrucci","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"10.1016\/j.intimp.2023.110072_b0255","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab157","article-title":"SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD","volume":"162","author":"Ala","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.intimp.2023.110072_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109080","article-title":"The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents","volume":"111","author":"Theofilis","year":"2022","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0265","doi-asserted-by":"crossref","first-page":"e006277","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"15","key":"10.1016\/j.intimp.2023.110072_b0270","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.intimp.2023.110072_b0275","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.intimp.2023.110072_b0280","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","article-title":"SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism","volume":"146","author":"Santos-Gallego","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.intimp.2023.110072_b0285","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.2337\/db21-0270","article-title":"Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes","volume":"70","author":"Thirunavukarasu","year":"2021","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0290","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.intimp.2023.110072_b0295","doi-asserted-by":"crossref","unstructured":"Authors\/Task Force M, McDonagh TA, Metra M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022; 24(1): 4-131.","DOI":"10.1002\/ejhf.2333"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0300","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","article-title":"Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment","volume":"4","author":"Konstam","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0305","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1161\/01.CIR.76.1.44","article-title":"Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction","volume":"76","author":"White","year":"1987","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0310","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1161\/01.CIR.96.1.116","volume":"96","author":"Migrino","year":"1997","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.intimp.2023.110072_b0315","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/imj.14260","article-title":"Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study","volume":"49","author":"Cohen","year":"2019","journal-title":"Intern Med J"},{"issue":"21","key":"10.1016\/j.intimp.2023.110072_b0320","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.intimp.2023.110072_b0325","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0330","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-019-0914-1","article-title":"Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction","volume":"18","author":"Zhang","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0335","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/CIRCRESAHA.120.317933","article-title":"Targeting Mitochondria-Inflammation Circuit by beta-Hydroxybutyrate Mitigates HFpEF","volume":"128","author":"Deng","year":"2021","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0340","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00395-020-0798-y","article-title":"Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities","volume":"115","author":"Cuijpers","year":"2020","journal-title":"Basic Res Cardiol"},{"issue":"6","key":"10.1016\/j.intimp.2023.110072_b0345","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2023.110072_b0350","article-title":"NOX1 mediates metabolic heart disease in mice and is upregulated in monocytes of humans with diastolic dysfunction","author":"Xu","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0355","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jacc.2020.11.044","article-title":"Etiology-Dependent Impairment of Diastolic Cardiomyocyte Calcium Homeostasis in Heart Failure With Preserved Ejection Fraction","volume":"77","author":"Frisk","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0360","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/CIRCULATIONAHA.119.040332","article-title":"Increased Myocardial Stiffness in Patients With High-Risk Left Ventricular Hypertrophy: The Hallmark of Stage-B Heart Failure With Preserved Ejection Fraction","volume":"141","author":"Hieda","year":"2020","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.intimp.2023.110072_b0365","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1161\/CIRCRESAHA.119.316311","article-title":"Myofilament Phosphorylation in Stem Cell Treated Diastolic Heart Failure","volume":"129","author":"Soetkamp","year":"2021","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.intimp.2023.110072_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166208","article-title":"Mitochondrial function, dynamics and quality control in the pathophysiology of HFpEF","volume":"1867","author":"Del Campo","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0375","doi-asserted-by":"crossref","first-page":"e005131","DOI":"10.1161\/CIRCHEARTFAILURE.118.005131","article-title":"Mitochondrial Morphology, Dynamics, and Function in Human Pressure Overload or Ischemic Heart Disease With Preserved or Reduced Ejection Fraction","volume":"12","author":"Chaanine","year":"2019","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0380","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00395-018-0712-z","article-title":"Inflammatory cells and their non-coding RNAs as targets for treating myocardial infarction","volume":"114","author":"Jung","year":"2018","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"10.1016\/j.intimp.2023.110072_b0385","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/CIRCRESAHA.120.315865","article-title":"S100A9 Links Inflammation and Repair in Myocardial Infarction","volume":"127","author":"Marinkovic","year":"2020","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0390","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/FJC.0000000000000876","article-title":"The Role of Immune Cells in Cardiac Remodeling After Myocardial Infarction","volume":"76","author":"Zhang","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0395","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12929-017-0322-3","article-title":"Macrophage activation and polarization in post-infarction cardiac remodeling","volume":"24","author":"Gombozhapova","year":"2017","journal-title":"J Biomed Sci"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0400","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.intimp.2023.110072_b0405","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0410","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10557-020-06978-y","article-title":"Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay","volume":"34","author":"Chen","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"10.1016\/j.intimp.2023.110072_b0415","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","article-title":"Cardiac Fibrosis: The Fibroblast Awakens","volume":"118","author":"Travers","year":"2016","journal-title":"Circ Res"},{"issue":"19","key":"10.1016\/j.intimp.2023.110072_b0420","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197165","article-title":"Innate Immunity Effector Cells as Inflammatory Drivers of Cardiac Fibrosis","volume":"21","author":"Baci","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.intimp.2023.110072_b0425","doi-asserted-by":"crossref","first-page":"8996","DOI":"10.1002\/jcp.29732","article-title":"The effector cells and cellular mediators of immune system involved in cardiac inflammation and fibrosis after myocardial infarction","volume":"235","author":"Liu","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.intimp.2023.110072_b0430","first-page":"7","volume":"10","author":"Kurose","year":"2021","journal-title":"Cardiac Fibrosis and Fibroblasts. Cells"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0435","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14728222.2020.1712593","article-title":"Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening","volume":"24","author":"Yu","year":"2020","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0440","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis\/Stiffness in Nondiabetic Heart Failure: A Multimodality Study","volume":"14","author":"Santos-Gallego","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"13","key":"10.1016\/j.intimp.2023.110072_b0445","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/CIRCULATIONAHA.121.057237","article-title":"Empagliflozin Reverses Late Na(+) Current Enhancement and Cardiomyocyte Proarrhythmia in a Translational Murine Model of Heart Failure With Preserved Ejection Fraction","volume":"145","author":"Hegyi","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2023.110072_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0455","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","article-title":"Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy","volume":"19","author":"Arow","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.intimp.2023.110072_b0460","doi-asserted-by":"crossref","unstructured":"Wang K, Li Z, Sun Y, et al. Dapagliflozin Improves Cardiac Function, Remodeling, Myocardial Apoptosis, and Inflammatory Cytokines in Mice with Myocardial Infarction. J Cardiovasc Transl Res 2021.","DOI":"10.1007\/s12265-021-10192-y"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0465","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12933-021-01322-6","article-title":"The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats","volume":"20","author":"Daud","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0470","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-021-01312-8","article-title":"Dapagliflozin: a sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFbeta1\/Smad signaling","volume":"20","author":"Zhang","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.intimp.2023.110072_b0475","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ajh\/hpz016","article-title":"Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload","volume":"32","author":"Shi","year":"2019","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0480","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"16","key":"10.1016\/j.intimp.2023.110072_b0485","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKalpha\/TGF-beta\/Smad signalling in type 2 diabetic rats","volume":"25","author":"Tian","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"7","key":"10.1016\/j.intimp.2023.110072_b0490","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41556-018-0124-1","article-title":"The multifaceted contributions of mitochondria to cellular metabolism","volume":"20","author":"Spinelli","year":"2018","journal-title":"Nat Cell Biol"},{"issue":"14","key":"10.1016\/j.intimp.2023.110072_b0495","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1093\/cvr\/cvaa340","article-title":"Molecular mechanisms and clinical implications of multiple forms of mitophagy in the heart","volume":"117","author":"Saito","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0500","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/rej.2005.8.3","article-title":"Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging","volume":"8","author":"Lemasters","year":"2005","journal-title":"Rejuvenation Res"},{"issue":"3","key":"10.1016\/j.intimp.2023.110072_b0505","doi-asserted-by":"crossref","first-page":"e104705","DOI":"10.15252\/embj.2020104705","article-title":"Molecular mechanisms and physiological functions of mitophagy","volume":"40","author":"Onishi","year":"2021","journal-title":"EMBO J"},{"key":"10.1016\/j.intimp.2023.110072_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2019.09.006","article-title":"Emerging role of mitophagy in cardiovascular physiology and pathology","volume":"71","author":"Morales","year":"2020","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.intimp.2023.110072_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2022.102288","article-title":"Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPKalpha1\/ULK1\/FUNDC1\/mitophagy pathway","volume":"52","author":"Cai","year":"2022","journal-title":"Redox Biol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0520","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010437","article-title":"Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis","volume":"23","author":"Song","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.intimp.2023.110072_b0525","doi-asserted-by":"crossref","first-page":"1122494","DOI":"10.1155\/2022\/1122494","article-title":"Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function","volume":"2022","author":"Wang","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.intimp.2023.110072_b0530","doi-asserted-by":"crossref","unstructured":"Li X, Flynn ER, do Carmo JM, et al. Direct Cardiac Actions of Sodium-Glucose Cotransporter 2 Inhibition Improve Mitochondrial Function and Attenuate Oxidative Stress in Pressure Overload-Induced Heart Failure. Front Cardiovasc Med 2022; 9: 859253.","DOI":"10.3389\/fcvm.2022.859253"},{"issue":"7347","key":"10.1016\/j.intimp.2023.110072_b0535","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0540","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10456-020-09748-4","article-title":"BMP6\/TAZ-Hippo signaling modulates angiogenesis and endothelial cell response to VEGF","volume":"24","author":"Pulkkinen","year":"2021","journal-title":"Angiogenesis"},{"issue":"15","key":"10.1016\/j.intimp.2023.110072_b0545","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155294","article-title":"VEGF-A in Cardiomyocytes and Heart Diseases","volume":"21","author":"Braile","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.intimp.2023.110072_b0550","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.738325","article-title":"The Role of the VEGF Family in Coronary Heart Disease","volume":"8","author":"Zhou","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.intimp.2023.110072_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.113475","article-title":"Chinese medicine GeGen-DanShen extract protects from myocardial ischemic injury through promoting angiogenesis via up-regulation of VEGF\/VEGFR2 signaling pathway","volume":"267","author":"Zhai","year":"2021","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0560","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cvr\/cvz301","article-title":"Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction","volume":"116","author":"Konijnenberg","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"22","key":"10.1016\/j.intimp.2023.110072_b0565","article-title":"Recapitulation of developmental mechanisms to revascularize the ischemic heart. JCI","volume":"2","author":"Dube","year":"2017","journal-title":"Insight"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0570","doi-asserted-by":"crossref","first-page":"15836","DOI":"10.1038\/s41598-021-95110-7","article-title":"Gastrin mediates cardioprotection through angiogenesis after myocardial infarction by activating the HIF-1alpha\/VEGF signalling pathway","volume":"11","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0575","doi-asserted-by":"crossref","first-page":"H278","DOI":"10.1152\/ajpheart.00471.2017","article-title":"VEGF nanoparticles repair the heart after myocardial infarction","volume":"314","author":"Oduk","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"8","key":"10.1016\/j.intimp.2023.110072_b0580","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2023.110072_b0585","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0590","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-8587(19)30405-X","article-title":"Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression","volume":"8","author":"van Sloten","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0595","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/endrev\/bnaa025","article-title":"Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease","volume":"42","author":"Horton","year":"2021","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.intimp.2023.110072_b0600","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s00125-020-05142-3","article-title":"Diabetes mellitus impairs circulating proangiogenic granulocytes","volume":"63","author":"Cappellari","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.intimp.2023.110072_b0605","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol"},{"issue":"10","key":"10.1016\/j.intimp.2023.110072_b0610","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41401-022-00889-4","article-title":"Intramuscular injection of sotagliflozin promotes neovascularization in diabetic mice through enhancing skeletal muscle cells paracrine function","volume":"43","author":"Luo","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.intimp.2023.110072_b0615","doi-asserted-by":"crossref","first-page":"8502059","DOI":"10.1155\/2022\/8502059","article-title":"Dapagliflozin Ameliorates the Formation and Progression of Experimental Abdominal Aortic Aneurysms by Reducing Aortic Inflammation in Mice","volume":"2022","author":"Liu","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.intimp.2023.110072_b0620","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fphar.2019.00362","article-title":"Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation","volume":"10","author":"Behnammanesh","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.intimp.2023.110072_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113882","article-title":"Distinctive effects of SGLT2 inhibitors on angiogenesis in zebrafish embryos","volume":"156","author":"Huttunen","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"10.1016\/j.intimp.2023.110072_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101156","article-title":"The Pathophysiological Basis of Diabetic Cardiomyopathy Development","volume":"47","author":"Avagimyan","year":"2022","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0635","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12933-019-0820-6","article-title":"SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob\/ob(-\/-) mice","volume":"18","author":"Adingupu","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.intimp.2023.110072_b0640","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031177","article-title":"Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats","volume":"22","author":"Trang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.intimp.2023.110072_b0645","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.862394","article-title":"Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis","volume":"13","author":"El-Shafey","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"10.1016\/j.intimp.2023.110072_b0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165807","article-title":"Empagliflozin improves left ventricular diastolic function of db\/db mice","volume":"1866","author":"Moellmann","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"11","key":"10.1016\/j.intimp.2023.110072_b0655","first-page":"6346","article-title":"A study of the effects of SGLT-2 inhibitors on diabetic cardiomyopathy through miR-30d\/KLF9\/VEGFA pathway","volume":"24","author":"Zhang","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0660","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1152\/physrev.00030.2020","article-title":"Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications","volume":"101","author":"Ren","year":"2021","journal-title":"Physiol Rev"},{"issue":"6","key":"10.1016\/j.intimp.2023.110072_b0665","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/db19-0991","article-title":"Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice","volume":"69","author":"Sun","year":"2020","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.intimp.2023.110072_b0670","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1038\/s41401-022-00885-8","article-title":"Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling","volume":"43","author":"Lin","year":"2022","journal-title":"Acta Pharmacol Sin"},{"issue":"11","key":"10.1016\/j.intimp.2023.110072_b0675","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/dom.14814","article-title":"The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis","volume":"24","author":"Moellmann","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.intimp.2023.110072_b0680","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1159\/000475942","article-title":"The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway","volume":"41","author":"Zhou","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.intimp.2023.110072_b0685","article-title":"Effects of mineralocorticoid receptor antagonist eplerenone on cardiac sympathetic nerve activity and left ventricular remodeling after reperfusion therapy in patients with first ST-segment elevation myocardial infarction","author":"Toda","year":"2021","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0690","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00395-022-00939-2","article-title":"Metabolism regulator adiponectin prevents cardiac remodeling and ventricular arrhythmias via sympathetic modulation in a myocardial infarction model","volume":"117","author":"Zhou","year":"2022","journal-title":"Basic Res Cardiol"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0695","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10741-018-9747-3","article-title":"Chronic heart failure: a disease of the brain","volume":"24","author":"Singh","year":"2019","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0700","doi-asserted-by":"crossref","first-page":"e13315","DOI":"10.1111\/apha.13315","article-title":"A novel sympathetic neuronal GABAergic signalling system regulates NE release to prevent ventricular arrhythmias after acute myocardial infarction","volume":"227","author":"Shi","year":"2019","journal-title":"Acta Physiol (Oxf)"},{"issue":"2","key":"10.1016\/j.intimp.2023.110072_b0705","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/CIRCULATIONAHA.119.042573","article-title":"Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure","volume":"142","author":"Karam","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0710","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.intimp.2023.110072_b0715","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41440-020-0410-8","article-title":"Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease","volume":"43","author":"Wan","year":"2020","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1016\/j.intimp.2023.110072_b0720","doi-asserted-by":"crossref","first-page":"51","DOI":"10.5582\/ddt.2017.01069","article-title":"Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report","volume":"12","author":"Kiuchi","year":"2018","journal-title":"Drug Discov Ther"},{"issue":"4","key":"10.1016\/j.intimp.2023.110072_b0725","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10557-017-6742-1","article-title":"Erythropoietin Attenuates Cardiac Dysfunction in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Diabetic Cardiomyopathy","volume":"31","author":"Lu","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.intimp.2023.110072_b0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109617","article-title":"Dapagliflozin attenuates diabetic cardiomyopathy through erythropoietin up-regulation of AKT\/JAK\/MAPK pathways in streptozotocin-induced diabetic rats","volume":"347","author":"El-Sayed","year":"2021","journal-title":"Chem Biol Interact"},{"issue":"15","key":"10.1016\/j.intimp.2023.110072_b0735","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1042\/CS20190585","article-title":"Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice","volume":"133","author":"Xue","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.intimp.2023.110072_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106448","article-title":"Sodium-glucose cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes","volume":"184","author":"Marfella","year":"2022","journal-title":"Pharmacol Res"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923003934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923003934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:59:07Z","timestamp":1761587947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923003934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":148,"alternative-id":["S1567576923003934"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110072","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110072"}}